Hamostaseologie

Scope & Guideline

Illuminating Hemostasis: Bridging Research and Clinical Application

Introduction

Explore the comprehensive scope of Hamostaseologie through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Hamostaseologie in depth and align your research initiatives with current academic trends.
LanguageGerman
ISSN0720-9355
PublisherGEORG THIEME VERLAG KG
Support Open AccessNo
CountryGermany
TypeJournal
Convergefrom 1981 to 2024
AbbreviationHAMOSTASEOLOGIE / Hamostaseologie
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRUDIGERSTR 14, D-70469 STUTTGART, GERMANY

Aims and Scopes

The journal "Hamostaseologie" focuses on advancing the understanding and management of hemostasis, thrombosis, and related disorders. It emphasizes clinical research, guidelines, and innovative treatment strategies within these domains.
  1. Clinical Management of Hemostasis and Thrombosis:
    The journal covers various aspects of clinical management, including guidelines and recommendations for treating patients with bleeding disorders, thrombosis, and other related conditions.
  2. Research on Coagulation Mechanisms:
    It provides insights into the underlying biological processes involved in coagulation and thrombosis, including studies on platelet function, clotting factors, and the impact of genetic mutations.
  3. Innovative Therapeutic Approaches:
    The journal highlights novel therapies, such as gene therapy, direct oral anticoagulants (DOACs), and other emerging treatment options for various hemostatic disorders.
  4. Patient-Centric Studies:
    Research that emphasizes the patient experience, including management strategies for specific populations (e.g., pediatric patients, cancer patients) and their unique needs in hemostasis and thrombosis.
  5. Public Health and Policy in Hemostasis:
    The journal addresses public health concerns, including the implications of hemostatic disorders on healthcare systems and policies, as well as guidelines for practice in different healthcare settings.
The recent publications in "Hamostaseologie" reflect emerging trends and themes that are gaining traction in the field of hemostasis and thrombosis research. These themes indicate a shift towards more contemporary issues and innovative approaches within the discipline.
  1. Cancer-Associated Thrombosis:
    Research focusing on the relationship between cancer and thromboembolic events is on the rise, highlighting the need for specialized management strategies for this vulnerable population.
  2. Personalized Medicine Approaches:
    There is a growing emphasis on individualized therapy, particularly in the context of hemophilia and other bleeding disorders, as seen in studies exploring tailored treatment regimens based on patient-specific factors.
  3. Impact of COVID-19 on Hemostasis:
    The pandemic has spurred increased research into the effects of COVID-19 on coagulation pathways and thromboembolic complications, marking a significant shift in research priorities.
  4. Integration of Technology in Management:
    Emerging themes include the use of digital health solutions and innovative technologies for monitoring and managing hemostatic disorders, reflecting the ongoing digital transformation in healthcare.
  5. Gene Therapy and Novel Anticoagulants:
    There is a notable trend towards exploring gene therapy and new anticoagulant agents as potential game-changers in the treatment landscape for hemophilia and thrombosis.

Declining or Waning

While "Hamostaseologie" has consistently focused on various aspects of hemostasis and thrombosis, certain themes have seen a decline in prominence in recent years. This may reflect evolving research interests or shifting clinical priorities.
  1. Traditional Laboratory Diagnostics:
    There has been a noticeable decrease in papers focused on traditional diagnostic methods for coagulation disorders, likely due to the advent of more advanced and efficient testing technologies that have overshadowed older approaches.
  2. Historical Treatments and Practices:
    Topics related to older treatment modalities, such as traditional anticoagulants or outdated surgical techniques, have become less frequent as newer, evidence-based practices gain prominence in the literature.
  3. Basic Research on Non-Hemostatic Disorders:
    Research that broadly intersects with hemostasis but focuses less on direct implications for thrombosis or bleeding disorders has decreased, as the journal shifts towards more clinically relevant studies.

Similar Journals

BLOOD COAGULATION & FIBRINOLYSIS

Bridging Molecular Insights and Clinical Applications
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0957-5235Frequency: 8 issues/year

BLOOD COAGULATION & FIBRINOLYSIS, a distinguished journal in the field of hematology, is published by Lippincott Williams & Wilkins, a reputable name in academic publishing. Since its inception in 1990, this journal has been committed to advancing the understanding of blood coagulation and fibrinolysis, focusing on the molecular mechanisms, clinical implications, and therapeutic aspects of these critical processes. With an impact factor reflecting its significance within the academic community, currently ranking Q3 in both Hematology and Miscellaneous Medicine for 2023, this journal serves as a pivotal platform for researchers and professionals alike. By providing access to cutting-edge research and reviews, BLOOD COAGULATION & FIBRINOLYSIS endeavors to foster collaboration and innovation in the treatment of coagulation disorders. Interested readers can explore ongoing contributions to the field through subscriptions and institutional access options.

CURRENT OPINION IN HEMATOLOGY

Unveiling the latest trends in hematology for professionals.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Therapeutic Advances in Hematology

Transforming research into impactful therapies.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

Hematology-American Society of Hematology Education Program

Bridging Research and Practice in Hematology
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

BLOOD

Illuminating Innovations in Hematology and Immunology.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Transforming Patient Care Through Cutting-Edge Research
Publisher: ELSEVIER SCIENCE INCISSN: 1538-7933Frequency: 12 issues/year

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, published by Elsevier Science Inc, stands at the forefront of research in the fields of hematology and medicine, boasting an impressive ranking of #5 out of 137 in Scopus's Medicine - Hematology category, with a remarkable 96th percentile. As an essential resource for researchers, clinicians, and students, this journal, identifiable through its ISSN 1538-7933 and E-ISSN 1538-7836, encompasses pioneering studies and reviews that focus on the mechanisms of thrombosis and hemostasis, contributing significantly to advancements in patient care and therapeutic strategies. With an established presence from 2003 through 2024, it has consistently achieved a prestigious Q1 category ranking, reflecting its impactful contributions to the scientific community. Although it operates under a subscription-based model, the journal remains committed to disseminating significant findings that inform best practices in clinical settings and shape future research trajectories.

PLATELETS

Fostering collaboration in hematological research.
Publisher: TAYLOR & FRANCIS INCISSN: 0953-7104Frequency: 8 issues/year

PLATELETS is a distinguished journal published by Taylor & Francis Inc that has been at the forefront of research in the fields of hematology and medicine since its inception in 1990. With an ISSN of 0953-7104 and an E-ISSN of 1369-1635, this journal boasts a solid reputation, as reflected by its Q2 ranking in both Hematology and Miscellaneous Medicine categories in 2023. PLATELETS serves as an essential platform for disseminating pioneering research, reviews, and case studies related to platelet biology, thrombosis, hemostasis, and their clinical implications. Although not an open-access publication, it is indexed in reputable databases, ensuring visibility and citation of quality contributions. Researchers, clinicians, and students alike will find valuable insights that may inform their work and enhance their understanding of the crucial role of platelets in health and disease. This journal's commitment to advancing knowledge and fostering innovation makes it a pivotal resource in the academic community.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Exploring the complexities of blood coagulation.
Publisher: SPRINGERISSN: 0929-5305Frequency: 8 issues/year

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.

JCO Precision Oncology

Elevating Treatment Strategies Through Genetic Insights
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 1 issue/year

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

HEMOGLOBIN

Decoding the mysteries of blood disorders.
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-0269Frequency: 6 issues/year

HEMOGLOBIN, a prominent journal published by Taylor & Francis Ltd, serves as a vital resource in the fields of Biochemistry, Clinical Biochemistry, Genetics, and Hematology. Established in 1976, the journal provides a platform for innovative research and review articles that explore the complexities of hemoglobin pathology and related disorders, making significant contributions to our understanding of hematological diseases. With an ISSN of 0363-0269 and an E-ISSN of 1532-432X, HEMOGLOBIN has garnered attention within the academic community, reflected in its category quartiles for 2023, which rank it in the Q3 and Q4 levels across relevant medical and biochemistry categories. Although it operates on a subscription basis rather than as an open-access journal, it remains influential, providing critical insights to researchers, professionals, and students aiming to address the current challenges in blood research and related fields. The journal not only emphasizes high-quality scientific analyses but also seeks to foster collaboration and dialogue among academia and clinical practitioners, ultimately advancing the frontier of knowledge in hemoglobin and hematological research.